Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.

ABSTRACT:

Background

Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor with significant activity in metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. It can cause hyperphosphatemia due to the "on-target" class effect of FGFR1 inhibition.

Objective

To investigate the relationship between hyperphosphatemia and treatment response in patients with mUC.

Intervention

Oral infigratinib 125 mg/d for 21 d every 28 d.

Design, setting, and participants

Data from patients treated with infigratinib in a phase I trial with platinum-refractory mUC and activating FGFR3 alterations were retrospectively analyzed for clinical efficacy in relation to serum hyperphosphatemia. The relationship between plasma infigratinib concent

SUBMITTER: Lyou Y 

PROVIDER: S-EPMC8425313 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature